JW Pharmaceutial

2018.3.15 JW Bioscience signs a technology transfer contract for'multi-biomarker diagnostic kit'

JW Biosciences signed a technology transfer contract with Yonsei University on March 15, 2018 for a'multi-biomarker diagnostic kit' that can detect pancreatic cancer early with only a simple blood test. JW Bioscience, which has secured a high value-added in vitro diagnostic infrastructure for pancreatic cancer following sepsis, has strengthened its global competitiveness in the field of diagnostic reagents.

2015.3.4 JW Holdings signs an MOU with Saudi Arabia's SPC to build an infusion plant

On March 4, 2015, JW Holdings signed a memorandum of understanding (MOU) for the construction of a $150 million infusion drug plant with Saudi Arabian pharmaceutical company SPC. The signing of this MOU paved the way for the domestic pharmaceutical industry to take a leap forward in that it builds a plant for the production of infusion solutions overseas using pure domestic technology, beyond general pharmaceutical exports.

2014.3 JW Creagen Approves CreaVax-HCC Phase 3 Clinical IND

In March 2014, CreaVax-HCC received approval for phase 3 clinical trials, paving the way for a breakthrough in the development of liver cancer treatments.reaVax-HCC phase 2 clinical results published in 2017 through Oncoimmunology confirmed that it significantly lowered the recurrence rate of liver cancer patients without significant side effects, demonstrating excellent technology worldwide.

2008.3.27 Choongwae Medical, relocated to Chungju factory

Choongwae Medical completed the Chungju plant on March 27, 2008, and dramatically improved the production infrastructure in the medical device field.The Chungju plant was designed as a facility that can meet various global certifications such as the US FDA, UL, Europe CE, and China CCC.

2005.3.9 Signed a contract to export the technology of imipenem first generic raw material with Biokimico

On March 9, 2005, Choongwae Pharmaceutical signed a contract to export the technology of imipenem first generic raw materials with Biokimico in Brazil. Prior to this, in 2004, Choongwae Pharmaceutical was recognized for its technological prowess by developing the world's first, the first generic 'Pripenem,' of the antibiotic imipenem, which no one has been successful with due to its high synthetic difficulty.

2004.3.2 Contracted with Maruko of Japan to license and export raw materials for itraconazole

On March 2, 2004, Choongwae Pharmaceutical signed a license and raw material export contract with Maruko of Japan for an antifungal drug'Itraconazole'. Choongwae Pharmaceutical has succeeded in improving stability and bioavailability by improving the poorly soluble itraconazole through continuous research.

1998.3.4 Choongwae Medical and HITACHI signed a strategic alliance with each other

On March 4, 1998, Choongwae Medical entered into a strategic alliance with Hitachi Medical, a global medical device company.On July 20, the two companies established a joint venture dedicated to A/S from the development of medical imaging diagnostic devices for the first time in Korea. This served as a progressive opportunity to strengthen the competitiveness of Chinese and foreign Medical.